Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 26 12:30PM ET
25.34
Dollar change
+0.11
Percentage change
0.44
%
Index- P/E9.91 EPS (ttm)2.56 Insider Own14.35% Shs Outstand446.04M Perf Week3.56%
Market Cap14.93B Forward P/E5.78 EPS next Y4.39 Insider Trans0.00% Shs Float380.55M Perf Month-4.27%
Income1.14B PEG- EPS next Q0.98 Inst Own70.64% Short Float4.11% Perf Quarter-10.11%
Sales2.27B P/S6.59 EPS this Y-11.23% Inst Trans-1.11% Short Ratio5.75 Perf Half Y-4.98%
Book/sh15.40 P/B1.65 EPS next Y10.31% ROA6.76% Short Interest15.65M Perf Year-6.97%
Cash/sh1.69 P/C14.95 EPS next 5Y-1.30% ROE17.62% 52W Range24.05 - 31.66 Perf YTD-9.79%
Dividend Est.0.68 (2.67%) P/FCF5.29 EPS past 5Y2.23% ROI8.49% 52W High-19.95% Beta0.46
Dividend TTM0.84 (3.31%) Quick Ratio1.54 Sales past 5Y5.78% Gross Margin- 52W Low5.37% ATR (14)0.51
Dividend Ex-DateNov 15, 2024 Current Ratio1.54 EPS Y/Y TTM536.55% Oper. Margin68.14% RSI (14)45.68 Volatility2.50% 1.96%
Employees89 Debt/Eq1.11 Sales Y/Y TTM-2.52% Profit Margin50.52% Recom1.27 Target Price41.86
Option/ShortYes / Yes LT Debt/Eq0.96 EPS Q/Q658.56% Payout31.57% Rel Volume0.33 Prev Close25.23
Sales Surprise5.46% EPS Surprise-1.09% Sales Q/Q5.29% EarningsNov 06 BMO Avg Volume2.72M Price25.34
SMA20-0.80% SMA50-3.63% SMA200-7.89% Trades Volume435,399 Change0.44%
Date Action Analyst Rating Change Price Target Change
Jun-03-24Downgrade UBS Buy → Neutral $28
Jun-14-22Resumed UBS Buy $47
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Dec-24-24 04:45AM
Dec-19-24 08:06PM
Nov-27-24 04:15PM
11:11AM
Nov-14-24 04:30PM
07:10AM Loading…
Nov-07-24 07:10AM
02:10AM
12:08AM
Nov-06-24 07:16PM
07:15AM
Nov-04-24 04:15PM
04:01PM
Nov-03-24 06:11AM
Oct-16-24 04:15PM
Oct-11-24 08:15AM
05:31PM Loading…
Oct-09-24 05:31PM
03:50PM
Sep-03-24 05:14PM
05:06PM
Aug-28-24 04:15PM
Aug-26-24 06:16AM
Aug-23-24 05:32AM
Aug-17-24 03:58PM
Aug-16-24 06:09PM
Aug-09-24 01:05AM
Aug-08-24 04:16PM
07:00AM
Jul-24-24 08:30AM
Jul-19-24 08:15AM
Jul-17-24 04:15PM
12:10PM Loading…
Jul-15-24 12:10PM
Jul-02-24 07:44PM
06:58PM
Jun-26-24 06:00AM
Jun-24-24 12:56PM
Jun-05-24 06:14AM
Jun-04-24 04:15PM
Jun-03-24 05:15PM
May-28-24 07:10AM
May-27-24 06:28PM
May-25-24 11:10PM
May-22-24 04:10PM
04:00PM
May-20-24 02:41PM
May-13-24 08:15AM
May-10-24 01:07AM
May-09-24 03:35PM
12:00PM
11:56AM
10:46AM
08:10AM
07:00AM
06:45AM
May-08-24 08:51AM
May-06-24 09:16AM
May-02-24 04:01PM
10:01AM
Apr-30-24 08:37AM
Apr-19-24 08:15AM
Apr-17-24 08:15AM
Mar-17-24 08:50AM
Feb-28-24 04:15PM
Feb-20-24 12:45PM
Feb-17-24 12:15AM
Feb-16-24 03:30PM
09:45AM
12:04AM
Feb-15-24 11:08PM
07:58AM
07:30AM
Jan-31-24 01:04AM
Jan-30-24 04:15PM
Jan-19-24 08:15AM
Jan-08-24 07:00AM
Dec-18-23 05:30AM
Nov-27-23 04:15PM
Nov-13-23 08:10AM
08:00AM
Nov-09-23 04:33PM
12:15AM
Nov-08-23 07:00AM
Oct-19-23 07:59AM
Oct-16-23 04:15PM
Oct-11-23 04:15PM
Sep-21-23 08:25AM
Sep-05-23 04:15PM
04:01PM
08:25AM
Aug-24-23 06:30AM
Aug-08-23 07:00AM
Jul-18-23 04:15PM
Jul-17-23 04:15PM
Jun-18-23 08:58AM
Jun-07-23 08:15AM
May-22-23 07:52PM
May-13-23 08:15AM
May-11-23 10:42AM
May-09-23 07:00AM
May-03-23 04:15PM
Apr-20-23 06:15AM
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RIGGS RORY BDirectorJan 02 '24Sale28.52235,2006,707,081254,899Jan 04 05:16 PM
RIGGS RORY BDirectorJan 03 '24Sale27.79199,0985,532,27655,801Jan 04 05:16 PM
RIGGS RORY BDirectorJan 04 '24Sale27.5535,702983,50420,099Jan 04 05:16 PM
Avara Management Ltd10% OwnerDec 29 '23Sale28.0465,8031,845,4062,477,520Jan 03 04:31 PM
Avara Management Ltd10% OwnerDec 28 '23Sale28.20209,8635,918,9342,543,323Dec 29 04:29 PM
Avara Management Ltd10% OwnerDec 27 '23Sale28.0141,7291,168,7542,753,186Dec 29 04:29 PM